104 related articles for article (PubMed ID: 7576982)
21. Cytotoxic synergism between trimetrexate and etoposide. Evidence that trimetrexate potentiates etoposide-induced protein-associated DNA strand breaks in L1210 leukemia cells through alterations in intracellular ATP concentrations.
Fry DW
Biochem Pharmacol; 1990 Nov; 40(9):1981-8. PubMed ID: 2146963
[TBL] [Abstract][Full Text] [Related]
22. Hypoxia promotes etoposide (VP-16) resistance in neuroblastoma CHP126 cells.
Wang D; Zhu Q; Zhang X; Zhang L; He Q; Yang B
Pharmazie; 2010 Jan; 65(1):51-6. PubMed ID: 20187579
[TBL] [Abstract][Full Text] [Related]
23. Comparative studies of pulse and continuous exposure in human tumor clonogenic assay.
Kanzawa F; Matsushima Y; Chiang CD; Nakano H; Nakagawa K; Takahashi H; Sasaki Y; Saijo N
J Pharmacobiodyn; 1987 Sep; 10(9):449-51. PubMed ID: 3437386
[TBL] [Abstract][Full Text] [Related]
24. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.
Bowman KJ; Newell DR; Calvert AH; Curtin NJ
Br J Cancer; 2001 Jan; 84(1):106-12. PubMed ID: 11139322
[TBL] [Abstract][Full Text] [Related]
25. Synthesis, hydrolytic activation and cytotoxicity of etoposide prodrugs.
Wrasidlo W; Schröder U; Bernt K; Hübener N; Shabat D; Gaedicke G; Lode H
Bioorg Med Chem Lett; 2002 Feb; 12(4):557-60. PubMed ID: 11844671
[TBL] [Abstract][Full Text] [Related]
26. In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy.
Wolff SN; Grosh WW; Prater K; Hande KR
Cancer Chemother Pharmacol; 1987; 19(3):246-9. PubMed ID: 3581418
[TBL] [Abstract][Full Text] [Related]
27. MDM2 mediated nuclear exclusion of p53 attenuates etoposide-induced apoptosis in neuroblastoma cells.
Rodriguez-Lopez AM; Xenaki D; Eden TO; Hickman JA; Chresta CM
Mol Pharmacol; 2001 Jan; 59(1):135-43. PubMed ID: 11125034
[TBL] [Abstract][Full Text] [Related]
28. Effect of combined treatment with radiation and low dose etoposide on cell survival.
Shigematsu N; Kawata T; Ihara N; Kawaguchi O; Kutsuki S; Ishibashi R; Kubo A; Ito H
Anticancer Res; 2001; 21(1A):325-8. PubMed ID: 11299757
[TBL] [Abstract][Full Text] [Related]
29. Predicting resistance or response to chemotherapy by proton magnetic resonance spectroscopy in neuroblastoma.
Lindskog M; Spenger C; Jarvet J; Gräslund A; Kogner P
J Natl Cancer Inst; 2004 Oct; 96(19):1457-66. PubMed ID: 15467035
[TBL] [Abstract][Full Text] [Related]
30. Kinetics of cytotoxicity of VM-26 and VP-16-213 on L1210 leukemia and hematopoietic stem cells.
Vietti TJ; Valeriote FA; Kalish R; Coulter D
Cancer Treat Rep; 1978 Sep; 62(9):1313-20. PubMed ID: 688275
[TBL] [Abstract][Full Text] [Related]
31. A proteomic investigation into etoposide chemo-resistance of neuroblastoma cell lines.
Urbani A; Poland J; Bernardini S; Bellincampi L; Biroccio A; Schnölzer M; Sinha P; Federici G
Proteomics; 2005 Feb; 5(3):796-804. PubMed ID: 15682461
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.
Vassal G; Terrier-Lacombe MJ; Bissery MC; Vénuat AM; Gyergyay F; Bénard J; Morizet J; Boland I; Ardouin P; Bressac-de-Paillerets B; Gouyette A
Br J Cancer; 1996 Aug; 74(4):537-45. PubMed ID: 8761367
[TBL] [Abstract][Full Text] [Related]
33. [Pharmacokinetic aspects of oral administration of etoposide].
Tillmann B; Krümpelmann S; Würthwein G; Wagner A; Schulze-Westhoff P; Hempel G; Jürgens H; Boos J
Klin Padiatr; 1998; 210(4):159-64. PubMed ID: 9743946
[TBL] [Abstract][Full Text] [Related]
34. A Population Dynamic Energy Budget-Based Tumor Growth Inhibition Model for Etoposide Effects on Wistar Rats.
Tosca EM; Pigatto MC; Dalla Costa T; Magni P
Pharm Res; 2019 Jan; 36(3):38. PubMed ID: 30635794
[TBL] [Abstract][Full Text] [Related]
35. Inhibitors of topoisomerase II as pH-dependent modulators of etoposide-mediated cytotoxicity.
Langer SW; Schmidt G; Sørensen M; Sehested M; Jensen PB
Clin Cancer Res; 1999 Oct; 5(10):2899-907. PubMed ID: 10537359
[TBL] [Abstract][Full Text] [Related]
36. Lidocaine potentiation of bleomycin A2 cytotoxicity and DNA strand breakage in L1210 and human A-253 cells.
Lazo JS; Braun ID; Meandzija B; Kennedy KA; Pham ET; Smaldone LF
Cancer Res; 1985 May; 45(5):2103-9. PubMed ID: 2580616
[TBL] [Abstract][Full Text] [Related]
37. Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene.
Lorico A; Rappa G; Srimatkandada S; Catapano CV; Fernandes DJ; Germino JF; Sartorelli AC
Cancer Res; 1995 Oct; 55(19):4352-60. PubMed ID: 7671247
[TBL] [Abstract][Full Text] [Related]
38. BIRICODAR (VX-710; Incel): an effective chemosensitizer in neuroblastoma.
Yanagisawa T; Newman A; Coley H; Renshaw J; Pinkerton CR; Pritchard-Jones K
Br J Cancer; 1999 Jun; 80(8):1190-6. PubMed ID: 10376971
[TBL] [Abstract][Full Text] [Related]
39. Interaction of radiation and etoposide on two cell lines with different radiosensitivities in vitro.
Takahashi T; Mitsuhashi N; Akimoto T; Matsumoto H; Ishikawa H; Saito Y; Niibe H
Anticancer Res; 2003; 23(4):3459-64. PubMed ID: 12926090
[TBL] [Abstract][Full Text] [Related]
40. N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo.
Ganapathi R; Grabowski D; Sweatman TW; Seshadri R; Israel M
Br J Cancer; 1989 Dec; 60(6):819-26. PubMed ID: 2605093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
